The discussion focuses on whether patients in complete molecular remission still need an allogeneic stem cell transplant, alongside methods to prevent T-cell fratricide using CRISPR and base editing. Dr. DiPersio also covers cross-specialty efforts led by pediatric groups like Charles Mulligan and St. Jude’s to decode transcriptional subsets, pointing to international trials across the United States, Europe, and China evaluating off-the-shelf allogeneic products and targeted interventions.